Ponoi II Management, LLC
Follow13F filer, CIK 1746488, San Francisco, CA
Ponoi II Management, LLC reported $137,252,000 across 5 holdings for the quarter ended 2020-12-31, in a 13F-HR filed 2021-02-16.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-21-002046
Changes against Q3 2020 are not shown: it was a notice, with the holdings in another manager's report (0 positions on file), so every position would read as new.
- Period
- 2020-12-31
- Reported value
- $137M
- Holdings
- 5
- Top 10 weight
- 100%
- New
- Sold out
Holdings, Q4 2020
Share positions as resolved from 13F-HR 0000950123-21-002046, largest first. % of portfolio is the value over $137,252,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 1,574,229 | $45.3M | 33.03% | ||||
| NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INC | 1,298,908 | $39.4M | 28.67% | ||||
| RVMDREVOLUTION MEDICINES INC | 685,011 | $27.1M | 19.76% | Timeline | |||
| NRIXNURIX THERAPEUTICS INC | 686,274 | $22.6M | 16.44% | Timeline | |||
| RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC | 145,401 | $2.87M | 2.09% |
How Q4 2020 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-21-002046 | base | 2021-02-16 | acceptance time not in the bulk data set |